EUVIMEDEUVIMED entdecken
Multizentrische StudieLeitlinieOpen Access

Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease

David Lam iD, Barry I Freedman, Joji Tokita, Fergus Fleming, Mayte Suarez-Farinas, Benjamin Bagwell, Julienne Kirk, Hazel Tapp, Lindsay Shade, Aida Vega, Stephanie Wang, Catherine Sinfield und 3 weitere

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8428-8437

DOI: 10.1111/dom.70993 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.06.2026. Verfasst von David Lam und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Renalytix.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

KidneyIntelX is a prognostic blood test for the progression of diabetic kidney disease (DKD) within 5 years. Long‐term utility is important. Materials and Methods Adults with type 2 diabetes (T2D) and CKD (G1‐G3b) from two medical centres were assessed for the following: (1) baseline KidneyIntelX risk levels and their association with GDMT usage; (2) changes in temporal kidney and metabolic trajectories after testing; (3) probability for a kidney composite outcome of sustained eGFR decline of 40% or kidney failure by baseline KidneyIntelX risk strata; and (4) risk at 12‐month for repeat‐tested participants.

Results

2470 patients with T2D and CKD (median baseline eGFR 63 mL/min/1.73 m 2 , UACR 51 mg/g, and HbA1c 7.2%), KidneyIntelX risk was 49.9% low, 40.6% intermediate, and 9.5% high. SGLT2i usage post‐test increased to 56%, 45%, 34% in high, intermediate, low‐risk groups. SGLT2i combined with GLP‐1 increased to 32%, 25%, 17% per risk group. Improvements in eGFR slope (−4.6 to −2.6 mL/min/1.73 m 2 /year), UACR (relative decrease of 23%), and HbA1c (relative decrease of 7.6%) were greatest in the high‐risk group. Hazard ratio (HR) for DKD progression for high vs. low was 10.4 [4.4–24.8] and intermediate vs. low HR was 4.0 [2.0–8.7]. With repeat testing ( n = 1143), 29% transitioned to lower risk accompanied by biomarker reductions, specifically KIM‐1, and initiation of SGLT2i or GLP‐1 doubled odds of risk reduction.

Conclusions

KidneyIntelX was associated with targeted GDMT usage with favourable changes in kidney and metabolic clinical measures and risk trajectories, with lower risk linked to therapy initiation and reduction in biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, Type 2HumansFemaleDisease ProgressionMaleMiddle AgedRisk AssessmentGlomerular Filtration RateSodium-Glucose Transporter 2 InhibitorsAgedPrognosisHypoglycemic AgentsPractice Guidelines as TopicKidneyBiomarkers

Stichwörter der Autor:innen

GLP‐1SGLT2 inhibitorcohort studydiabetic nephropathyreal‐world evidence

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsBiomarkers

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Internal Medicine, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Barbara T Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Renalytix AI, PLC, New York, New York, USA.

ORCID-Profile: David Lam, Steven G Coca, Girish N Nadkarni

Förderung

  • Renalytix

Zitieren

APA

Lam, D., Freedman, B. I., Tokita, J., Fleming, F., Suarez-Farinas, M., Bagwell, B., Kirk, J., Tapp, H., Shade, L., Vega, A., Wang, S., Sinfield, C., Coca, S. G., Nadkarni, G. N., & Donovan, M. J. (2026). Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease. Diabetes, Obesity and Metabolism, 28(9), 8428-8437. https://doi.org/10.1111/dom.70993

Vancouver

Lam D, Freedman BI, Tokita J, Fleming F, Suarez-Farinas M, Bagwell B, et al. Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease. Diabetes, Obesity and Metabolism. 2026;28(9):8428-8437. doi:10.1111/dom.70993

BibTeX
@article{Lam2026,
  author = {Lam, David and Freedman, Barry I and Tokita, Joji and Fleming, Fergus and Suarez-Farinas, Mayte and Bagwell, Benjamin and Kirk, Julienne and Tapp, Hazel and Shade, Lindsay and Vega, Aida and Wang, Stephanie and Sinfield, Catherine and Coca, Steven G and Nadkarni, Girish N and Donovan, Michael J},
  title = {Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8428--8437},
  doi = {10.1111/dom.70993}
}
Kostenlos starten →